Search
Bolt Biotherapeutics Inc
BOLTAdd to Watchlist
4.050USD
+0.060+1.50%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.78MMarket Cap
LossP/E TTM
More Details of Bolt Biotherapeutics Inc Company
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Bolt Biotherapeutics Inc Info
Ticker SymbolBOLT
Company nameBolt Biotherapeutics Inc
IPO dateFeb 05, 2021
CEOQuinn (William P)
Number of employees52
Security typeOrdinary Share
Fiscal year-endFeb 05
Address900 Chesapeake Drive
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16506659295
Websitehttps://boltbio.com/
Ticker SymbolBOLT
IPO dateFeb 05, 2021
CEOQuinn (William P)
Company Executives of Bolt Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.31K
-1724.25%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
445.00
-6741.80%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.31K
-1724.25%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
445.00
-6741.80%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Bolt Biotherapeutics Inc?
The top five shareholders of Bolt Biotherapeutics Inc are: Mr. William P. (Willie) Quinn
How many institutions hold shares of Bolt Biotherapeutics Inc (BOLT)?
As of 2026Q1, 63 institutions hold shares of Bolt Biotherapeutics Inc, with a combined market value of approximately 516.47K, accounting for 26.88% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -504316.00.